• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Boehringer Ingelheim GmbH - Product Pipeline Review - 2012 Product Image

Boehringer Ingelheim GmbH - Product Pipeline Review - 2012

  • ID: 2135988
  • December 2012
  • 297 pages
  • Global Markets Direct

Boehringer Ingelheim GmbH – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Boehringer Ingelheim GmbH - Product Pipeline Review - 2012” provides data on the Boehringer Ingelheim GmbH’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Boehringer Ingelheim GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from Boehringer Ingelheim GmbH and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Boehringer Ingelheim GmbH - Brief Boehringer Ingelheim GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Boehringer Ingelheim GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline READ MORE >

2
List of Tables 4
List of Figures 6
Boehringer Ingelheim GmbH Snapshot 7
Boehringer Ingelheim GmbH Overview 7
Key Information 7
Key Facts 7
Boehringer Ingelheim GmbH – Research and Development Overview 8
Key Therapeutic Areas 8
Boehringer Ingelheim GmbH – Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products – Monotherapy 16
Pipeline Products – Combination Treatment Modalities 17
Boehringer Ingelheim GmbH – Pipeline Products Glance 18
Boehringer Ingelheim GmbH – Late Stage Pipeline 18
Boehringer Ingelheim GmbH Clinical Stage Pipeline Products 21
Boehringer Ingelheim GmbH – Early Stage Pipeline Products 26
Boehringer Ingelheim GmbH – Drug Profiles 28
(empagliflozin + linagliptin) 28
(olodaterol + tiotropium bromide) 29
11Beta HSD-1 Program 31
Adalimumab Biosimilar 32
afatinib 33
afatinib + [paclitaxel] 35
afatinib + [pemetrexed disodium] 37
afatinib + [temozolomide] 38
afatinib + [trastuzumab] 40
Afatinib + Vinorelbine 41
ambroxol 43
BCA-909 44
BI-1021958 46
BI-10773 + Metformin 47
BI-10773 + Metformin + Sulfonylurea 49
BI-135585 51
BI-144807 52
BI-201335 + BI-207127 + [ribavirin] 53
BI-2536 55
BI-655066 57
BI-671800 58
BI-811283 59
BI-811283 + [cytarabine] 60
BI-831266 62
BI-836826 63
BI-836845 64
BI-836858 66
BI-847325 67
BI-853520 69
BIBW-2992 + Carboplatin 70
BIBW-2992 + Erbitux 71
BIBW-2992 + Paclitaxel + Bevacizumab 72
BIBW-2992 + Rapamune 74
BIBW-2992 + Taxol + Carboplatin 75
BILB-1941 77
Drug For Neurology 78
empagliflozin 79
FX-125-L 81
Mitotic Checkpoint Inhibitor 83
Nanobody Program 84
nintedanib 85
nintedanib + [carboplatin] + [doxorubicin] 87
nintedanib + [cisplatin] + [gemcitabine hydrochloride] 89
nintedanib + [docetaxel] 91
nintedanib + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] 93
nintedanib + [pemetrexed disodium] 95
olodaterol 97
OX-MPI 99
PDE-2 Inhibitor 100
pramipexole ER 101
rituximab biosimilar 103
tenecteplase + [clopidogrel] + [enoxaparin sodium] 104
tiotropium bromide 106
Vargatef + BIBW 2992 108
Vargatef + Vinorelbine 109
Vargatef + Vinorelbine + Carboplatin 110
Vargatef + Volasertib 112
volasertib 113
volasertib + [pemetrexed disodium] 115
Volasertib + Afatinib 116
ZP-2929 117
Boehringer Ingelheim GmbH – Pipeline Analysis 118
Boehringer Ingelheim GmbH – Pipeline Products by Therapeutic Class 118
Boehringer Ingelheim GmbH – Pipeline Products By Target 120
Boehringer Ingelheim GmbH – Pipeline Products by Route of Administration 121
Boehringer Ingelheim GmbH – Pipeline Products By Mechanism of Action 122
Boehringer Ingelheim GmbH – Recent Pipeline Updates 124
Boehringer Ingelheim GmbH - Dormant Projects 140
Boehringer Ingelheim GmbH - Discontinued Pipeline Products 142
Discontinued Pipeline Product Profiles 142
Boehringer Ingelheim GmbH – Company Statement 144
Boehringer Ingelheim GmbH – Locations And Subsidiaries 145
Head Office 145
Other Locations & Subsidiaries 145
Boehringer Ingelheim GmbH, Recent Developments 146
Boehringer Ingelheim GmbH- Press Release 146
Financial Deals Landscape 193
Boehringer Ingelheim GmbH, Deals Summary 193
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deal Details 198
Asset Transactions 198
Partnerships 206
Licensing Agreements 253
Equity Offering 277
Debt Offering 282
Asset Transactions 283
Acquisition 284
Appendix 288
Methodology 288
Coverage 288
Secondary Research 288
Primary Research 288
Expert Panel Validation 288
Contact Us 289
Disclaimer 289

List of Tables
Boehringer Ingelheim GmbH, Key Information 15
Boehringer Ingelheim GmbH, Key Facts 15
Boehringer Ingelheim GmbH – Pipeline by Indication, 2012 19
Boehringer Ingelheim GmbH – Pipeline by Stage of Development, 2012 23
Boehringer Ingelheim GmbH – Monotherapy Products in Pipeline, 2012 24
Boehringer Ingelheim GmbH – Combination Treatment Modalities in Pipeline, 2012 25
Boehringer Ingelheim GmbH – Filed, 2012 26
Boehringer Ingelheim GmbH – Phase III, 2012 27
Boehringer Ingelheim GmbH – Phase II, 2012 29
Boehringer Ingelheim GmbH – Phase I, 2012 30
Boehringer Ingelheim GmbH – Pre-Clinical, 2012 34
Boehringer Ingelheim GmbH – Discovery, 2012 35
Boehringer Ingelheim GmbH – Pipeline By Therapeutic Class, 2012 127
Boehringer Ingelheim GmbH - Pipeline By Target, 2012 128
Boehringer Ingelheim GmbH – Pipeline By Route of Administration, 2012 129
Boehringer Ingelheim GmbH – Pipeline Products By Mechanism of Action, 2012 131
Boehringer Ingelheim GmbH – Recent Pipeline Updates, 2012 132
Boehringer Ingelheim GmbH - Dormant Developmental Projects,2012 148
Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2012 150
Boehringer Ingelheim GmbH, Subsidiaries 153
Boehringer Ingelheim GmbH, Deals Summary 201
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics 206
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea 208
Boehringer Ingelheim Acquires Fremont Facility From Amgen 209
Boehringer Ingelheim Acquires Protein Material And Specific Functional Assay From Axxam 211
Boehringer Ingelheim Acquires Zantac From Pfizer 212
Orexo Extends Licensing Agreement With Boehringer 214
Ablynx Enters Into Licensing Agreement With Boehringer Ingelheim 216
Vectura Signs An Agreement With Boehringer Ingelheim 218
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich 219
BioGenes Enters Into Co-Development Agreement With Boehringer Ingelheim 221
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 222
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 224
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim 225
Pfenex Enters Into Collaboration With Boehringer Ingelheim 226
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 227
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim 229
Chiesi Farmaceutici Enters Into Co-Promotion Agreement With Boeringher Ingelheim For Foster 232
Boehringer Ingelheim Enters Co-Marketing Agreement With VTU Technology 233
Boehringer Ingelheim Enters Into Co-Development Agreement With MacroGenics 234
Boehringer Ingelheim Enters Into Collaboration Agreement With Micromet 236
Boehringer Ingelheim Enters Into Co-Development Agreement With Priaxon 238
Evotec Extends Research Collaboration With Boehringer Ingelheim 240
Boehringer Ingelheim Partners With Vitae Pharma 241
Kemwell Enters Into Strategic Collaboration Agreement With Boehringer Ingelheim 243
Boehringer Ingelheim Enters Into Collaboration With DeveloGen 244
Exelixis Enters Into Co-Development Agreement With Boehringer Ingelheim 245
Antitope Enters Into Research Agreement With Boehringer Ingelheim 246
Ablynx Extends Agreement With Boehringer Ingelheim 247
Proximagen Neuroscience Enters Into Agreement With Boehringer Ingelheim 248
Boehringer Ingelheim Enters Into An Agreement With Vitae Pharma 249
NascaCell Enters Into Co-Development Agreement With Boehringer Ingelheim 250
Ablynx Enters Into Co-Development Agreement With Boehriner Ingelheim 251
Boehringer Ingelheim Enters Into An Agreement With Proteros biostructures 253
Evotec Enters Into Co-Development Agreement With Boehringer Ingelheim 254
Axxam Enters Into Drug Discovery Collaboration With Boehringer Ingelheim 255
Graffinity Pharma Expands Its Research Agreement With Boehringer Ingelheim Pharma 256
Biota Holdings Enters Into An Agreement With Boehringer Ingelheim 257
FivePrime Therapeutics Enters Into Research Agreement With Boehringer Ingelheim 258
Evotec And Evotec Neurosciences Amends Co-Development Agreement With Boehringer Ingelheim 260
Ingenuity Systems Enters Into Licensing Agreement With Boehringer Ingelheim 261
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT 262
Polyphor Enters Into Licensing Agreement With Boehringer Ingelheim For MacroFinder Drug Discovery Technology 263
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 264
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 266
Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim 267
Depomed Enters Into Licensing Agreement With Boehringer Ingelheim 269
f-star Biotechnologische Enters Into Licensing Agreement With Boehringer Ingelheim 270
Boehringer Ingelheim Enters Into Licensing Agreement With Fresenius Kabi Deutschland 272
Marinomed Biotechnologie Enters Into Licensing Agreement With Boehringer Ingelheim 273
Boehringer Ingelheim Enters Into Licensing Agreement With Evec 275
Boehringer Ingelheim Enters Into Licensing Agreement With BioFocus DPI 276
Euroscreen Enters Into Licensing Agreement With Boehringer Ingelheim 277
GeneGo Expands Licensing Agreement With Boehringer Ingelheim 278
Boehringer Ingelheim Enters Into Licensing Agreement With Xencor 279
Boehringer Ingelheim Enters Into Licensing Agreement With MorphoSys 280
GeneGo Enters Into Licensing Agreement With Boehringer Ingelheim 281
XstalBio Signs Licensing Agreement With Boehringer Ingelheim 282
Ingenuity Systems Enters Into Licensing Agreement With Boehringer Ingelheim For IPA 283
Inspire Pharma Enters Into Licensing Agreement With Boehringer Ingelheim 284
Ablynx Completes IPO Of $121.19 Million 285
Vectura Group Completes Private Placement Of $7.22 Million 287
Vectura Group Completes Private Placement Of $12.83 Million 288
Boehringer Ingelheim Completes Private Placement Of Bonds For $1,250.5 Million 290
Eli Lilly Reacquires Rights To Yentreve From Boehringer Ingelheim 291
Boehringer Ingelheim Acquires An Additional 33.6% Stake In SSP 292
Boehringer Ingelheim Acquires Actimis Pharma 294

List of Figures
Boehringer Ingelheim GmbH – Pipeline by Indication, 2012 18
Boehringer Ingelheim GmbH – Pipeline by Stage of Development, 2012 23
Boehringer Ingelheim GmbH – Monotherapy Products in Pipeline, 2012 24
Boehringer Ingelheim GmbH – Combination Treatment Modalities in Pipeline, 2012 25
Boehringer Ingelheim GmbH – Pipeline By Therapeutic Class, 2012 126
Boehringer Ingelheim GmbH – Pipeline By Route of Administration, 2012 129
Boehringer Ingelheim GmbH - Pipeline Products By Mechanism of Action, 2012 130

Question Is the product BI-1021958 listed in this product?
Answer The product BI-1021958 is present in this product but the mode of action and target is not available as it is not yet disclosed by the company .
Note: Product cover images may vary from those shown

RELATED PRODUCTS